Neuronetics, Inc. (NASDAQ:STIM) Short Interest Up 22.2% in February

Neuronetics, Inc. (NASDAQ:STIM) saw a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 10,258,643 shares, a growth of 22.2% from the February 12th total of 8,392,324 shares. Based on an average daily trading volume, of 1,142,605 shares, the short-interest ratio is presently 9.0 days. Currently, 16.6% of the company’s shares are short sold. Currently, 16.6% of the company’s shares are short sold. Based on an average daily trading volume, of 1,142,605 shares, the short-interest ratio is presently 9.0 days.

Neuronetics News Roundup

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Q4 results and 2026 revenue guidance — Neuronetics reported Q4 revenue of $41.8M (beat consensus) and provided 2026 revenue guidance of $160M–$166M, reflecting strong clinic and pro forma growth driven by Greenbrook. This shows top-line momentum and a path to higher revenue. Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Experienced CEO hire — the company named Dan Reuvers as President & CEO (effective March 23). Reuvers has a track record of scaling revenue and managing direct-billing models, which investors may view as supportive for commercial execution and margin improvement. Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
• Positive Sentiment: Product and growth initiatives — management outlined a >9% revenue growth target for 2026 while piloting new TMS models and preparing for the Compass therapy launch, signaling potential future revenue upside if adoption and reimbursement follow. Neuronetics outlines >9% 2026 revenue growth target
• Neutral Sentiment: Earnings call detail available — transcripts and the Q4 call provide color on margin trends, cash flow and roll‑out plans (useful for assessing execution risk). Investors should review the call for specifics on reimbursement, clinic rollouts and the Better Me Provider Program timeline. Earnings Call Transcript
• Negative Sentiment: Profitability, leverage and insider sales — despite revenue growth, Neuronetics remains unprofitable (negative net margin and ROE), carries leverage and disclosed large inducement RSUs for the new CEO. Recent insider sales and a history of insider dispositions add investor concern about near-term dilution and governance optics. Quiver Quant — CEO Appointment & Insider Activity
• Negative Sentiment: High-volume selling and valuation risk — trading volume spiked well above average around the release, amplifying price movement. The company still has a limited market cap and an extended history of losses, which raises sensitivity to execution misses and funding/credit concerns. MarketBeat — Q4 Earnings Snapshot

Neuronetics Trading Down 9.9%

Shares of NASDAQ:STIM opened at $1.23 on Wednesday. The business has a 50-day moving average price of $1.63 and a 200-day moving average price of $2.05. The stock has a market cap of $83.90 million, a price-to-earnings ratio of -1.49 and a beta of 0.87. The company has a quick ratio of 2.09, a current ratio of 2.24 and a debt-to-equity ratio of 2.09. Neuronetics has a 52-week low of $0.80 and a 52-week high of $5.34.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Neuronetics had a negative net margin of 33.88% and a negative return on equity of 131.15%. The firm had revenue of $41.78 million for the quarter, compared to analyst estimates of $40.84 million. Equities analysts predict that Neuronetics will post -1.13 EPS for the current year.

Analyst Upgrades and Downgrades

STIM has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. Wall Street Zen upgraded Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Neuronetics currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Insiders Place Their Bets

In related news, CEO Keith J. Sullivan sold 33,847 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $1.65, for a total value of $55,847.55. Following the completion of the sale, the chief executive officer directly owned 1,533,165 shares in the company, valued at $2,529,722.25. This trade represents a 2.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 104,307 shares of company stock worth $164,097. Corporate insiders own 9.80% of the company’s stock.

Institutional Trading of Neuronetics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Madryn Asset Management LP purchased a new stake in Neuronetics in the 4th quarter worth approximately $25,497,000. Vanguard Group Inc. increased its holdings in Neuronetics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company’s stock valued at $7,732,000 after buying an additional 89,504 shares in the last quarter. UBS Group AG increased its holdings in Neuronetics by 20.4% in the fourth quarter. UBS Group AG now owns 2,607,047 shares of the company’s stock valued at $3,598,000 after buying an additional 442,216 shares in the last quarter. Lane Generational LLC acquired a new position in shares of Neuronetics in the fourth quarter worth about $2,353,000. Finally, Balyasny Asset Management L.P. boosted its stake in shares of Neuronetics by 6.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company’s stock worth $5,267,000 after acquiring an additional 92,048 shares in the last quarter. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.